Hydal (Hydromorphone Hydrochloride)

Hydal is indicated for the short‑term treatment of severe pain that cannot be adequately controlled with non‑opioid analgesics.

• Management of acute postoperative pain following major surgery.
• Relief of severe breakthrough cancer pain when other opioids are insufficient.
• Control of pain associated with traumatic injuries requiring hospitalization.
• Use in palliative care settings for patients with intense, refractory pain.
• Adjunct therapy for severe pain during intensive care unit (ICU) stays.
• Short‑term analgesia for patients undergoing painful diagnostic or therapeutic procedures.

• Hydal exerts its analgesic effect by acting as a full agonist at the μ‑opioid receptors located in the central nervous system. Binding to these G‑protein‑coupled receptors inhibits adenylate cyclase activity, reduces intracellular cAMP levels, and promotes opening of potassium channels while closing calcium channels. The resulting neuronal hyperpolarization diminishes the transmission of nociceptive signals and alters pain perception. These actions collectively produce a dose‑dependent reduction in the subjective experience of pain.

Adverse reactions to Hydal may vary in frequency and severity; they are typically categorized as common or serious.

Common

• Nausea, vomiting, or constipation, often occurring shortly after dosing.
• Drowsiness, dizziness, or mild sedation that may affect alertness.
• Dry mouth and reduced gastrointestinal motility leading to discomfort.
• Itching, flushing, or mild rash at the injection site.

Serious

• Respiratory depression or shallow breathing that can be life‑threatening.
• Severe hypotension or cardiovascular collapse requiring immediate intervention.
• Profound sedation leading to loss of consciousness or inability to respond.
• Allergic reactions such as anaphylaxis, angioedema, or severe skin eruptions.

When prescribing or administering Hydal, clinicians should observe specific precautions to minimize risk and ensure safe use.

• Assess the patient’s respiratory function before initiating therapy and monitor continuously during treatment.
• Avoid use in individuals with known hypersensitivity to hydromorphone or other opioid analgesics.
• Use the lowest effective dose for the shortest duration necessary to achieve analgesia.
• Exercise caution in patients with a history of substance use disorder, depression, or suicidal ideation.
• Adjust dosing or consider alternative therapy in patients with severe hepatic or renal impairment.
• Do not combine with other central nervous system depressants without close supervision.

Hydal can interact with other medications, potentially altering its analgesic effect or increasing the risk of adverse events.

Avoid

• Concurrent use with other opioid agonists or high‑potency analgesics, which may amplify respiratory depression.
• Co‑administration with benzodiazepines, barbiturates, or other central nervous system depressants without strict monitoring.
• Combining with monoamine oxidase inhibitors (MAOIs) or within 14 days of MAOI therapy, due to risk of severe reactions.

Use with caution

• Concomitant use of selective serotonin reuptake inhibitors (SSRIs) or tramadol, which may increase serotonin syndrome risk.
• Concurrent administration of CYP3A4 inhibitors (e.g., ketoconazole, erythromycin) that can raise hydromorphone plasma levels.
• Use with antihistamines or anticholinergic agents that may exacerbate constipation or urinary retention.